1. Ali I, Saleem K, Uddin R, Haque A, El-Azzouny A. Natural products:human friendly anti-cancer medications. Egypt Pharm J(NRC), 2010;9:133-79.
2. Lu DY, Lu TR, Lu Y, Sastry N, Wu HY. Discover natural chemical drugs in modern medicines. Metabolomics. 2016;6(3):181.
3. Pattanayak S. Alternative to antibiotics from herbal origin-outline of comprehensive research project. Current Pharmacogenetics Personalized Medicine. 2018;16(1):9-62.
4. Parasuraman S. Herbal drug discovery:challenges and perspectives. Current Pharmacogenetics Personalized Medicine. 2018;16(1):63-68.
5. Zhang ZJ. Cold factors and treatments Treatise on. People's Medical and Public Health Publication. Beijing, PR China, 2005.
6. Li SZ. Compendium of Materia Medica.
7. Huang Di Nei Jing, Su Wen. The Emperor's Medical Experience, Questions and Answer.
8. Lu DY, Lu TR, Wu HY. Treatment of influenza virus infections with Chinese medicine. Adv Pharmacoepidemiology Drug Safety. 2012;1:104.
9. Lu DY, Lu TR, Wu HY. Avian flu, pathogenesis and therapy. Anti-Infective Agents. 2012;10(2):124-129.
10. Lu DY, Lu TR, Wu HY, Yarla NS, Ding J, et al. HIV/AIDS curable study, new forms of therapeutic trinity. Rec Pat Antiinfect Drug Discov. 2018;13(3):217- 227.
11. Lu DY, Wu Hy, Yarla NS, Lu TR, Xu B, Ding J. Ebola therapeutic study and future trends. Infect Disorder Drug Targets. 2019;19(1):17-29.
12. Hu B, Du Q, Shen KP, Xu L. Principles and scientific basis of traditional Chinese medicine in cancer treatment. J Bioanal Biomed. 2012. S6:005. Doi:10. 4172/1948-593X. S6-005.
13. Alam F, Islam MA, Kamal MA, Gam SH. Updates on managing type 2 diabetes mellitus with natural products, towards antidiabetic drug developments. Current Medicinal Chemistry. 2016;23(29):1-37.
14. Lu DY, Che JY, Yarla NS, Wu HY, Lisa D, Lu TR, Zhu H. Diabetes prevention and treatments, a specific topic for modern medicines. J Metabolic Syndrome. 2017;8(3):231.
15. World Health Organization. WHO, Obesity and overweight 2018.
16. Lu DY, Che JY, Wu HY, Yarla NS, Xu B, et al. Obesity, risks and managements. Metabolomics. 2018;8(1):155.
17. Lu DY, Che JY, Lu Y, Wu HY, Yarla NS, et al. An overview of obesity. Metabolomics. 2018;8(2):200.
18. Lu DY, Che JY, Lu TR, Lu Y, Huang YK, et al. Pathology and treatments of obesity. Trends in Medicine. 2018;8(5):157.
19. Lu DY, Che JY, Yarla NS, Putta S, Shen Y. Bone disease recovery strategies, An overview. EC Orthopaedics. 2019;10(1):1-3.
20. Lu DY, Che JY, Yarla NS, Putta S, Lin LP, et al. Human obesity, pathological and therapeutic advances. EC Pharmacology & Toxicology. 2019;7(4):231-238.
21. Aggarwei R, Jain SK. Obesity and metabolic phenotypes. EC Diabetes & Metabolic Res. 2017;1(1):11-12.
22. Rafael H. Therapeutic methods against insulin resistance. J Endocrinol Metab. 2016;6(1):1-11.
23. Lu DY, Che JY, Shen Y. Osteoporosis, importance for early diagnosis and treatment. EC Orthopaedics. 2018, 9(9):624-625.
24. Lu DY. HIV/AIDS Treatments, Fight for a Cure. LAMBERT Academic Publishing. Ed Da-Yong Lu, 2017.
25. Lu DY, Wu HY, Yarla NS, Xu B, Ding J, et al. HAART in HIV/AIDS treatments, future trends. Infectious Disorders-Drug Targets. 2018.
26. Lu DY, Lu TR, Che JY, Ding J, Xu B, et al. Advances and shortcoming of HIV/AIDS therapy. Innovations in Pharmaceuticals and Pharmacotherapy. 2015;3:511-518.
27. Liu DF, Liu YL, Chen H, Zeng WL, Wen XM, et al. Evaluation on the curative effect and safety of Chinese traditional medicine in treatment of mild a/hH1N1 influenza in sichuan area. Modern Preventive Medicine. 2011;38(2):338-343.
28. Zhou Ho, Tao LT, Xu HC, Jiang YG, Deng YQ, et al. Discussion on Laws of Traditional Chinese Medical Treatment of H1N1 Influenza Based on Cohort Study. World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica, 2011;13:777-782.
29. Rumschlag-Booms E, Zhang HJ, Soejarto DD, Fong HHS, Rong LJ. Development of an antiviral screening protocol:one-stone-two-birds. J Antivir Antiretrovir, 2011;7:8-10.
30. Li YH, Yan QB, Yu KZ, Tong HM, Sun Y. Study of the compound Chinese medicine against the anti-avian influenza virus. Scientia Agricultura Sinica, 2009;41:1511-158.
31. Lu DY, Lu TR, Wu HY. Zika therapy by traditional Chinese medicine, a new proposal. Adv Pharmacol Clinical Trial. 2016;1(1), 103.
32. Lu DY, Che JY, Yarla NS, Zhu H, Lu TR, et al. Type 2 diabetes study, introduction and perspective. The Open Diabetes Journal. 2018;8:13-21.
33. Lu DY, Che JY, Yarla NS, Wu HY, Lu TR, et al. Type 2 diabetes treatment and drug development study. The Open Diabetes J. 2018;8:22-33.
34. Laroo H. The escalating incidence of late onset of diabetes II--strategies and remedies for use on a personal basis. EC Diabetes & Metabolic Res. 2018;1(3):58-70.
35. Ahmad S. An Old Disease, A New Insights. Ed, 2013.
36. Lu DY, Che JY. Rethink of diabetes treatment and drug development. Cell & Developmental Biology. 2014;3(2):125.
37. Lu DY, Che JY, Yarla NS, Wu HY, Xu B, et al. Type 2 diabetes, medical knowledge and pharmaceutical innovations. J Diabetology. 2017;1(1):1-3.
38. Singh A, Srivastav R, Randey AK. Protective role of Terminalia Chebula in streptozotocin-induced diabetic mice for wound healing activity. Brit J Medicine & Medical Res. 2017;22(2):1-8.
39. Li GQ, Kam A, Wong KH, Zhou X, Omar EA, et al. Herbal medicines for the management of diabetes. An Old Disease, A New Insights. (ed, Shamm Ahmad), 2012;28:396-413.
40. Imam K. Management and treatment of diabetes mellitus. An Old Disease, A New Insights. (ed, Shamm Ahmad), 2013;26:356-380.
41. Lu DY, Che JY. Rethink of diabetes treatment and drug development. Cell & Developmental Biology, 2014;3(2):125.
42. Wagh VD. Propolis:a wonder bees product and its pharmacological potentials. Adv Pharmacol Sci. 2013;2013:308249.
43. Merris J. Productivity counts--but the definition is key. Science. 2005;309(5735):726-727.
44. Gupta SC, Sung B, Prasad S, Aggarwal BB. Cancer drug discovery by repurposing:teaching new tricks to old dogs. Trends in Pharmacological Sciences. 2013;34(9):507-517.
45. Ali I, Haque A, Wani WA, Saleem K, Al za'zbi M. Analyses of anticancer drugs by capillary electrophoresis;a review. Biomedical Chromatography. 2013;27(10):1296-1311.
46. Ruggeri BA, Camp F, Miknyoczki S. Animal models of disease:Preclinical animal models of cancer and their applications and utility in drug discovery. Biochemical Pharmacology, 2014;87:150-161.
47. Lu DY, Chen EH, Lu TR. Anticancer drug development, a matter of money or a matter of idea? Metabolomics. 2015;5(2):134.
48. Lu DY, Lu TR, Zhu H, Ding J, Xu B, et al. Anticancer drug development, getting out from bottleneck. Int J Mol Biol, 2017;2(1):00010.
49. Lu DY, Lu TR, Chen EH, Xu B, Yarla NS, et al. Anticancer drug development, system updating and global participations. Current Drug Therapy. 2017;12(1):37-45.
50. Lu DY, Cao JY, Xu B. Biological activities and clinical utilizations of harringtonine and homoharringtonine. Nat Product Res Development. 2000;12(5):70-73.
51. Prasad S, Tyagi AK. Traditional Medicine, the goldmine for modern drugs. Adv Tech Biol Med. 2015;3(1):108.
52. Aravindaram K, Yang NS. Anti-inflammatory plant natural products for cancer therapy. Planta Med, 2010;76:1103-1117.
53. Yang G, Li X, Li X, Wang L, Li J, et al. Traditional Chinese medicine in cancer care:a review of case series published in the Chinese literature. Evid Based Complement Alternate Med. 2012;751046.
54. Manheimer E, Wieland S, Kimbrough E, Cheng K, Berman BM. Evidence from the Cochrane collaboration for traditional Chinese Medicine therapies. J Alternative and Complementary Medicine, 2009;15(9):1001-14. Manheimer
E, Wieland S, Kimbrough E, Cheng K, Berman BM. Evidence from the Cochrane collaboration for traditional Chinese Medicine therapies. J Altern Complement Med, 2009;15(9):1001-14.
55. Lo LC, Chen CY, Chen ST, Chen HC, Lee TC, et al. Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy:study protocol for a randomized, double-blind, placebo-controlled trial. Trials, 2012;13(1):232.
56. Li XQ, Ling CQ. Chinese herbal medicine for side effects of transarterial chemoembolization in liver cancer patients:a systematic review and metaanalysis. Zhong Xi Yi Jue He Xue Bao, 2012;10(12):1341-62.
57. Lu DY, Lu TR, Che JY, Wu HY. Old theories revisited on cancer assistant therapy. Int J Medical and Health Sciences Res. 2014;1(5):50-57.
58. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med. 2003;9:867-873.
59. Goldberg DE, Siliciano RF, Jacobs WR. Outwitting evolution:fighting drugresistant TB, malaria, and HIV. Cell, 2012;148:1271-1283.
60. Lu DY, Lu TR, Che JY, Wu HY, Xu B. New perspectives of HIV/AIDS therapy study. Recent Pat Antiinfect Drug Discov. 2014;9(2):112-120.
61. Cohen J. Animals show how Zika harms fetuses. Science. 2016;352(6287):752-753.
62. Pizza DMM, Loaiza AM, Montoya JFA, Manrique OA, Sossa VA, et al. A model for the risk of microcephaly induced by the Zika virus(ZIKV). Open Journal of Modeling and Simulation. 2016;4:109-117.
63. Lu DY, Lu TR, Chen XL, Ding J. Individualized cancer chemotherapy. Hypotheses in Clinical Medicine. Ed, Shoja MM, Agutter PS, Tubbs RS, Ghanei M, Ghabili K, Harris A, Loukas M. 2012;13:199-216.
64. Lu DY. Personalized cancer chemotherapy, an effective way for enhancing outcomes in clinics. Woodhead Publishing, Elsevier, UK. 2014.
65. Lu DY, Lu TR, Yarla NS, Wu HY, Xu B, et al. Drug combination in clinical cancer treatment. Rev Recent Clin Trials. 2017;12(3):202-211.
66. Lu DY, Chen EH, Wu HY, Lu TR, Xu B, et al. Anticancer drug combination, how far we can go through? Anticancer Agents Med Chem, 2017;17(1):21-28.
67. Lu DY, Chen EH, Ding J, Xu B, et al. Anticancer drug combinations, a big momentum is needed. Metabolomics. 2015;5(3):e139.
68. Putta S, Yarla NS, Peluso I, Tiwari DK, Reddy GV, et al. Anthocyanins:Possible role as multitarget therapeutic agents for prevention and therapy of chronic diseases. Curr Pharm Des. 2018.
69. Alekshun MN, Levy SB. Molecular mechanisms of anti-bacterial multidrug resistance. Cell. 2007;128:1037-1050.
70. Lander ES. Initial impact of the sequencing of the human genome. Nature, 2011;470:187-197.
71. Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153:17-37.
72. Lu DY, Lu TR, Yarla NS, Xu B, Ding J. HIV in human genomes and therapeutics. HIV Curr Res. 2017;2(1):121.
73. Lu DY, Lu TR, Yarla NS, Xu B, Ding J. HIV in human genomes and related therapeutics. HIV/AIDS Treatments, Fight for a Cure. LAMBERT Academic Publishing. Ed, Da-Yong Lu, 1st ed, 2017;6:68-76.
74. Rahimzadeh V, Bartlett G. Policies and practices of data-intensive primary care in the precision-medicine era. Internal Medicine Rev. 2017;3(9):1-14.
75. Lu DY, Lu TR, Ding J, Xu B, Che JY, et al. Anticancer drug sensitivity testing, a historical review and future perspectives. Current Drug Therapy. 2015;10(1):44-55.
76. Volm M, Efferth T. Prediction of cancer drug resistance and implications for personalized medicine. Frontiers in Oncology, 2015;282.
77. Stransky B, Galante P. Application of bioinformatics in cancer research. An IMICS Perspective on Cancer Research. 2010;211-233.
78. Lu DY, Qi RX, Lu TR, Wu HY. Cancer bioinformatics for update anticancer drug developments and personalized therapeutics. Rev Recent Clin Trials. 2017;12(2):101-110.
79. Garg PK. Potential of molecular imaging to advance molecular medicine. Cancer Stud Mol Medicine Open. 2017;3(1):e3-e4.
80. de Macedo JE. Knowledge of the molecular signaling pathways improves the chances of treatment of gastro-intestinal stromal tumors. Can Stud Mol Med Open. 2015;2(1):69-71.
81. Meyer UA. Pharmacogenetics--five decades of therapeutic lessons from genetic diversity. Nat Rev Genet. 2004;5(9):669-76.
82. Lu DY, Lu TR, Xu B, Ding J. Pharmacogenetics of cancer therapy:breakthroughs from beyond? Future Science OA. 2015;1(4):FSO. 15, 80.
83. Talmadge JE, Fidler IJ. The biology of cancer metastasis:historical perspective. Cancer Res, 2010;70(14):5649-5669.
84. Valastyan S. Weinberg RA. Tumor metastasis:molecular insights and evolving paradigms. Cell, 2011;147(2):275-292.
85. Lu DY, Lu TR, Wu HY, Cao S. Cancer Metastasis treatments. Current Drug Therapy, 2013, 8(1):24-29.
86. Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT:2016;166(1):21-45.
87. Lu DY, Lu TR, Xu B, Qi RX, Sastry NY, et al. Cancer metastasis, a clinical dilemma for therapeutics. Current Drug Therapy, 2016;11(2):163-169.
88. Lambert, AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell, 2017, 168, 670-691.
89. Smith RE, Tran K, Richards KM, Luo R. Dietary carbohydrates that modulate the immune system. Clinical Immunology, Endocrine and Metabolic Drugs. 2015;2(1):35-42.
90. Lu DY, Lu TR, Yarla NS, Xu B, Chen EH, Ding J. Anticancer drug development, breakthroughs are waiting. Adv Pharmacology & Clinical Trials. 2017;2(1):119.
91. Lu DY, Lu TR, Xu B, Yarla NS. Anticancer drug developments, challenge from historic perspective. EC Pharmacology & Toxicology. 2018;6(11):922-936.
92. Lu DY, Lu TR, Chen EH, Yarla NS, Xu B, Ding J, Huang M, Zhu H. Keep up the pace of drug development evolution and expenditure. Cancer Rep Rev. 2018;2(5):165.